NCT01179217 2020-08-19A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemiaEmmaus Medical, Inc.Phase 3 Completed230 enrolled 19 charts 1 FDA
NCT01895361 2020-01-31SUSTAINReprixys Pharmaceutical CorporationPhase 2 Completed198 enrolled 18 charts 1 FDA
NCT00236041 2014-05-09Efficacy/Safety Study of ACTIQ® for Opioid-Tolerant Children and Adolescents With Breakthrough Pain (BTP)Teva Branded Pharmaceutical Products R&D, Inc.Phase 2 Completed38 enrolled
NCT00236093 2014-05-09Extension Study of ACTIQ Treatment for Children and Adolescents With Breakthrough PainTeva Branded Pharmaceutical Products R&D, Inc.Phase 2 Completed